Arnold & Porter's False Claims Act (FCA) attorneys recently discussed key takeaways from the September 30, 2024, groundbreaking decision in Zafirov v. Florida Medical Associates LLC, holding the FCA's qui tam device unconstitutional.

Arnold & Porter's Erik Walsh provides financial institutions key takeaways from the SEC's proposed climate risk disclosure rules and how those dovetail with the proposed principles on climate risk management announced by the OCC and FDIC.

This session will provide an overview of the Federal Anti-Kickback Statute, focusing on emerging risks (and mitigation strategies) in the medical device industry.

In an effort to limit challenges for patient access, patient adherence to recommended treatment, or adoption of innovative products and services, providers, suppliers, and product manufacturers seek ways to address such roadblocks.

Raqiyyah Pippins talks about the exciting new trends in consumer health product regulation.

In this video, Monique and Amanda discuss what digital therapeutic executives need to know about the Healthcare Common Procedure Coding System (HCPCS) code set...

Murad Hussain talks about how life sciences companies and healthcare providers can work with enforcement investigators to encourage a more sophisticated analysis of data.

Jami Vibbert discusses the current application of privacy laws to healthcare and life sciences companies. Efforts to enforce those laws will show that they weren't ...

Our Legislative & Public Policy team is pleased to provide the July 2023 edition of "Capital Snapshot," a monthly summary of the issues, events, and timelines driving federal policy and political decisions.

Our Legislative & Public Policy team is pleased to provide the January 2024 edition of "Capital Snapshot," a monthly summary of the issues, events, and timelines driving federal policy and political decisions.

Our Legislative & Public Policy team is pleased to provide the April 2024 edition of "Capital Snapshot," a monthly summary of the issues, events, and timelines driving federal policy and political decisions.

Our Legislative & Public Policy team is pleased to provide the July 2024 edition of "Capital Snapshot," a monthly summary of the issues, events, and timelines driving federal policy and political decisions.

Our Legislative & Public Policy team is pleased to provide the April 2023 edition of "Capital Snapshot," a monthly summary of the issues, events, and timelines...

A significant number of biopharmaceutical companies have recently filed for bankruptcy, often seeking to sell assets through the bankruptcy process, including via section 363 sales.

In our recent advisory, we discuss the Finding of Violation issued by the US Department of the Treasury's Office of Foreign Assets Control (OFAC) to MidFirst Bank (MidFirst)...

This time, we're reviewing the civil cases from the Fourth District reviewed by the Supreme Court in the first third of this decade, from 2020 to 2022-to-date.

This time, we're reviewing the county-level data on the Third District civil cases reviewed by the Supreme Court between 2020 and 2022 (so far).

Our Legislative & Public Policy team is pleased to provide the February 2024 edition of "Capital Snapshot," a monthly summary of the issues, events, and timelines driving federal policy and political decisions.

Our Legislative & Public Policy team is pleased to provide the March 2024 edition of "Capital Snapshot," a monthly summary of the issues...

A push for ESG accountability in the EU and UK has been driven in part by investor and consumer demand and pressure on regulators to act swiftly...